ArticleCancers2021
Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Pharmacogenomic studies of fertility outcomes in pediatric cancer survivors - A systematic review.Clinical and translational science · 2024Pooled it
- Evaluation of ovarian functions in girls treated for hematological malignancy.Scientific reports · 2025Article
- Genetic and epigenetic bases of long-term adverse effects of childhood cancer therapy.Nature reviews. Cancer · 2025Review
- Anti-Mullerian Hormone and conception timing as predictors of live births in cancer patients using fertility preservation: a systematic review.Frontiers in oncology · 2025Review
- Interindividual variation in ovarian reserve after gonadotoxic treatment in female childhood cancer survivors - a genome-wide association study: results from PanCareLIFE.Fertility and sterility · 2024Article
- Molecular Factors Predicting Ovarian Chemotoxicity in Fertile Women: A Systematic Review.Cancers · 2024Review
- Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality.Ophthalmology · 2023Article
- Improving quality and quantity of life for childhood cancer survivors globally in the twenty-first century.Nature reviews. Clinical oncology · 2023Review
- Gonadal Function in Female Adolescent and Young Adult Survivors of Childhood Cancer.Cancer research and treatment · 2023Article
- Premature aging in childhood cancer survivors.Oncology letters · 2023Review
- White paper: Oncofertility in pediatric patients with Wilms tumor.International journal of cancer · 2022Article
- Age- and Diet-Dependent Changes in Hepatic Lipidomic Profiles of Phospholipids in Male Mice: Age Acceleration in Cyp2b-Null Mice.Journal of lipids · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 20 institutions in 10 countries.
M E Madeleine van der PerkPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.ORCID 0000-0003-0782-5307
Linda BroerDepartment of Internal Medicine, Rotterdam, ErasmusMC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
Yutaka YasuiDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0002-7717-8638
Leslie L RobisonDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Melissa M HudsonDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Joop S E LavenDepartment of Obstetrics and Gynecology, Erasmus MC-University Medical Center, 3015 GD Rotterdam, The Netherlands.
Helena J van der PalPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Wim J E TissingPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Birgitta VersluysPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Dorine BrestersPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Gertjan J L KaspersPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.ORCID 0000-0001-7716-8475
Andrica C H de VriesPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Cornelis B LambalkDepartment of Obstetrics and Gynaecology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Annelies OverbeekDepartment of Obstetrics and Gynaecology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Jacqueline J LoonenDepartment of Haematology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Catharina C M BeerendonkDepartment of Obstetrics and Gynaecology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Julianne ByrneBoyne Research Institute, 5 Bolton Square, East, Drogheda, A92 RY6K Co. Louth, Ireland.
Claire BergerDepartment of Paediatric Oncology, University Hospital, 42 055 Saint-Etienne, France.ORCID 0000-0001-9875-5150
Eva ClemensPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Uta DirksenUniversity Hospital Essen, Pediatrics III, West German Cancer Centre, 45147 Essen, Germany.ORCID 0000-0002-5435-7860
Jeanette Falck WintherChildhood Cancer Research Group, Danish Cancer Society Research Center, 2100 Copenhagen, Denmark.ORCID 0000-0002-3440-5108
Sophie D FossåDepartment of Oncology, Oslo University Hospital, 0372 Oslo, Norway.
Desiree GrabowDivision of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Monica MuracaEpidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.ORCID 0000-0001-5259-7046
Melanie KaiserDivision of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.ORCID 0000-0002-3362-2530
Tomáš KepákUniversity Hospital Brno, International Clinical Research Center (FNUSA-ICRC), Masaryk University, 656 91 Brno, Czech Republic.
Jarmila KruseovaMotol University Hospital, 150 05 Prague, Czech Republic.ORCID 0000-0002-6576-7048
Dalit Modan-MosesThe Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel Hashomer, and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.
Claudia SpixDivision of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Oliver ZolkInstitute of Clinical Pharmacology, Brandenburg Medical School Theodor Fontane, Immanuel Klinik Rüdersdorf, 16816 Neuruppin, Germany.
Peter KaatschDivision of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Jesse H KrijtheDepartment of Intelligent Systems, Delft University of Technology, 2628 BL Delft, The Netherlands.ORCID 0000-0003-3435-6358
Leontien C M KremerPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Russell J BrookeDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0001-7115-2990
Jessica L BaedkeDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0001-5085-4985
Ron H N van SchaikDepartment of clinical chemistry, Erasmus MC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
John N van den AnkerDivision of Clinical Pharmacology, Children's National Hospital, Washington, DC 20010, USA.
André G UitterlindenDepartment of Internal Medicine, Rotterdam, ErasmusMC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
Annelies M E BosDepartment of Reproductive Medicine and Gynecology, University Medical Center Utrecht, 3584 CS Utrecht, The Netherlands.
Flora E van LeeuwenDepartment of Epidemiology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Eline van Dulmen-den BroederPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Anne-Lotte L F van der KooiPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Marry M van den Heuvel-EibrinkPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
On Behalf Of The PanCareLIFE Consortium
Princess Máxima Center · NLErasmus MC · NLSt. Jude Children's Research Hospital · USJohannes Gutenberg University Mainz · DEAmsterdam University Medical Centers · NLRadboud University Nijmegen · NLAarhus University Hospital · DKBoyne Research Institute · IEChildren's National · USDelft University of Technology · NLEmma Kinderziekenhuis · NLGerman Cancer Research Center · DEInserm · FRIstituto Giannina Gaslini · ITMasaryk University · CZMedizinische Hochschule Brandenburg Theodor Fontane · DEOslo University Hospital · NOTel Aviv University · ILThe Netherlands Cancer Institute · NLUniversity Hospital in Motol · CZ
Funding
The St. Jude Lifetime CohortU01CA195547 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HUDSON, MELISSA M, NESS, KIRSTEN KIMBERLIE · 2015 to 2024
$14.9MKWF Kankerbestrijding VU 2006-3622.NCI NIH HHS U01 CA195547Princess Máxima Center Foundation NASeventh Framework Programme 602030Stichting Kinderen Kankervrij 20Stichting Kinder Oncologisch Centrum Rotterdam NA
Abstract
backgroundFemale childhood cancer survivors (CCSs) carry a risk of therapy-related gonadal dysfunction. Alkylating agents (AA) are well-established risk factors, yet inter-individual variability in ovarian function is observed. Polymorphisms in CYP450 enzymes may explain this variability in AA-induced ovarian damage. We aimed to evaluate associations between previously identified genetic polymorphisms in CYP450 enzymes and AA-related ovarian function among adult CCSs.
methodsAnti-Müllerian hormone (AMH) levels served as a proxy for ovarian function in a discovery cohort of adult female CCSs, from the pan-European PanCareLIFE cohort (
results
conclusionsFemale CCSs
Indexed as
anti-Müllerian hormonecandidate gene approachchemotherapychildhood cancer survivorscytochrome P450 genesovarian function
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.